Eotaxin-2 blockade ameliorates experimental autoimmune encephalomyelitis

Figure 1 Anti-eo-2 neutralizing mAb treatment effect on progressive experimental autoimmune encephalomyelitis clinical course. Progressive experimental autoimmune encephalomyelitis (EAE) was induced in female C57BL/6 mice by immunization with two following subcutaneous injections of MOG_35-55 peptide, emulsified in CFA, with an interval of 1 wk. EAE-induced mice were injected daily intraperitoneally with 25 μg or 100 μg D8, mouse IgG, or with vehicle control only (PBS) starting from day 0 post immunization, and monitored for EAE clinical score. A significant improvement in EAE clinical score compared to total IgG treated mice was observed only with the higher concentration of D8 on day 56, in which treatment with D8 100 μg led to a decline of 61.5% in average clinical score (n = 10 in each group, P = 0.04, one way ANOVA).